Preclinical & Clinical Evaluation of the Brain Penetrant NLRP3 Inhibitor, NT-0796 in Obesity & Cardiometabolic Disease
Time: 9:30 am
day: Conference Day One AM
Details:
- Highlighting favorable shifts in cardiovascular biomarkers linked to reduced inflammation-driven cardiometabolic risk
- Underscoring the role of hypothalamic inflammation as a therapeutic target in obesity
- Showcasing oral NLRP3 inhibition as a strategy to improve key metabolic parameters in individuals with obesity
